News and press

For the latest on the data investigation following the 2024 Cyberattack, please visit synnoviscyberupdate.co.uk.

For all related media queries, please contact:
Telephone : +44 (0) 20 3077 0549
Email: synnovisqueries@fticonsulting.com

Filter by:

1st August 2013

Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.

Joanne T Marsden, David C Rees

1st August 2013

How I treat heterozygous hereditary antithrombin deficiency in pregnancy

Untreated hereditary antithrombin deficiency in pregnancy is associated with maternal venous thromboembolism (VTE) and possibly with fetal loss.

Bramham K, Retter A, Robinson SE, Mitchell M, Moore GW, Professor Beverley Hunt

31st July 2013

21-Hydroxylase deficiency in the neonate – trends in steroid anabolism and catabolism during the first weeks of life

Sofia Christakoudi, David A. Cowan, Georgios Christakudis

28th July 2013

New therapies to reduce low-density lipoprotein cholesterol

Lipid-lowering is an intervention that reduces atherosclerosis and its complications.

Professor Anthony S. Wierzbicki, Viljoen A , Hardman TC, Mikhailidis DP

28th July 2013

Epicardial fat and vascular risk: a narrative review

We comment on the associations between epicardial adiposity and cardiovascular disease (CVD) and associated risk factors.

Katsiki N, Mikhailidis DP, Professor Anthony S. Wierzbicki

19th July 2013

"A sustainable financial turnaround" End of Year Accounts 2012

The organisation LLP published its audited Annual Accounts for the year ending 31 December 2012 on 19 July 2013.

17th July 2013

Introducing the Innovation Academy

The Organisation recently hosted their first Innovation Academy event in London (28 June 2013).

4th July 2013

Good science equals good medicine

Clinical science has been a powerful driver of development in the provision of healthcare for decades and many of our people have contributed to current practice.

27th June 2013

Lipid-lowering agents

The role of lipid lowering in reducing the risk of mortality and morbidity from cardiovascular disease (CVD) is well established.

Ewang-Emukowhate M, Professor Anthony S. Wierzbicki

27th June 2013

Measurement of infliximab and anti-infliximab antibodies - analytical aspects and clinical implications

Commercial assays for monitoring Infliximab (IFX) and anti-drug antibodies (ADAb) are currently available.

Nick Unsworth, P. Irving, M.G.Ward, G. Richards

Last updated: 23/09/2022

Search form

News and press

eMail alerts and news

Site details

Search form

News and press

Share this page

eMail alerts and news

Follow us

Site details